Here is what nobody told you
In a randomized clinical trial, tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients (Stanley et al., JAMA, 2014), and its Phase 3 program (Falutz et al.) established the visceral-fat effect that underpins its FDA approval
Complementary modeling studies suggest that GLP-1 RAs such as semaglutide and tirzepatide may disrupt the typical feedback loop in which weight loss leads to compensatory increases in appetite, potentially extending the period of reduction before plateauing occurs
Tirzepatide mimics natural hormones that regulate and decrease hunger
Cardiovascular Outcome Data Tirzepatide has the SURMOUNT-MMO trial underway, with results expected in 2026 that will directly measure cardiovascular event reduction
They dont taste like fiber supplements at all, which is a nice change for people used to traditional fiber supplements that arent that appealing to take